On This Day in Health: June 24, 2021
On June 24, 2021, the U.S. Food and Drug Administration issued an emergency use authorization for Actemra, or tocilizumab, to treat certain patients hospitalized with COVID-19. The authorization covered adults and children aged two and older who were receiving systemic corticosteroids and needed supplemental oxygen or more advanced respiratory support. Genentech, based in South San Francisco, announced the decision that day. It added a treatment aimed at the harmful inflammatory response that could accompany severe infection. The action did not authorize routine use for mild illness or prevention, and an emergency authorization was a different regulatory step from full approval for COVID-19.
Tocilizumab was already an established medicine for conditions involving abnormal immune activity, including rheumatoid arthritis. It blocks the receptor for interleukin-6, a signaling protein involved in inflammation. During severe COVID-19, an excessive inflammatory response could contribute to lung injury and other complications, making that pathway a possible target. A plausible mechanism, however, did not guarantee that the medicine would improve survival. Different studies had produced different results, and investigators needed to consider disease severity, timing, other treatments and the outcomes being measured. The FDA reviewed evidence from four randomized controlled trials involving more than 5,500 hospitalized patients before issuing the authorization.
The large RECOVERY study supplied important evidence. In its tocilizumab comparison, 4,116 adults were randomly assigned to receive the medicine plus usual care or usual care alone. Most were also receiving corticosteroids. By 28 days, deaths occurred in about 31 percent of the tocilizumab group and 35 percent of the comparison group. The result supported a survival benefit in the studied population, while showing that many seriously ill patients still died despite treatment. Other outcomes and trials contributed to the assessment. The June authorization translated the accumulating evidence into a defined U.S. treatment pathway rather than declaring that every patient with the virus would benefit.
Clinical limits remained central. Tocilizumab suppresses immune signaling and carries risks, including serious infection, so its use required medical assessment and monitoring. It was administered by intravenous infusion for the authorized COVID-19 use, alongside other hospital care. The 2021 decision also belonged to an evolving regulatory history: full FDA approval for hospitalized adults with the specified oxygen and corticosteroid requirements followed in December 2022. That later action should not be confused with the original emergency authorization. The June 24 milestone illustrates how an existing immune-modifying medicine gained a new role through controlled evidence, adding another way to address severe disease while preserving the need to match treatment to the patient and stage of illness.
Tocilizumab blocks the interleukin-6 receptor, affecting an inflammatory signaling pathway. Its use in other diseases made it a candidate for investigation, not automatic proof of benefit in COVID-19.
The authorized population was hospitalized and receiving systemic corticosteroids, with a need for oxygen or advanced respiratory support. The medicine was not authorized as a general preventive measure.
The FDA's review included four randomized trials. RECOVERY provided particularly important survival evidence in adults, most of whom also received corticosteroids.
A lower death rate in the treatment group did not eliminate the risks of severe COVID-19. The medicine's immune effects also required attention to infections and other adverse effects.
The June 2021 action was an emergency use authorization. Full approval for the specified hospitalized adult population came later, in December 2022.
The event illustrates the importance of assessing an existing medicine within a new disease context. Controlled comparisons, patient selection and the treatment combination mattered as much as the biological rationale.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.